Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mirikizumab Therapy is Effective for Patients With Moderate to Severe Ulcerative Colitis Patients Whose Geboes Score Grade is ≥3.2) on Endoscopic Biopsy

NCT06626165 is registered in ClinicalTrials.gov with Showa Inan General Hospital as lead sponsor.

NCT NCT06626165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06626165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mirikizumab Therapy is Effective for Patients With Moderate to Severe Ulcerative Colitis Patients Whose Geboes Score Grade is ≥3.2) on Endoscopic Biopsy
Lead sponsor
Showa Inan General Hospital
Phase
Phase 4
Overall status
Completed
Start date
July 20, 2024
Completion date
September 30, 2025
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis